Adjuvant Chemotherapy Options in HER2-Positive Breast Cancer
This video examines chemotherapy options for HER2-positive breast cancer in the adjuvant setting, and what evidence there is for alternatives to an anthracycline backbone.
In this video, Sara M. Tolaney, MD, MPH, of the Dana-Farber Cancer Institute in Boston, discusses chemotherapy options for HER2-positive breast cancer in the adjuvant setting.
Most pivotal adjuvant studies have used anthracyclines as a backbone, but this form of chemotherapy is associated with higher cardiac toxicity, among others.
Here Tolaney examines one study that used an alternative regimen (docetaxel, carboplatin, and trastuzumab, or TCH) and looks ahead at the potential for new biologic agents to change the treatment approach in these patients.
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
